Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Metapneumovirus Clear all
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Human Metapneumovirus
Interventions
HMPV challenge virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced May 22, 2026, 1:09 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Metapneumovirus
Interventions
Lumicitabine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Fresno, California • Long Beach, California • Eustis, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Metapneumovirus
Interventions
10^6 PFU rHMPV-Pa vaccine, 10^5 PFU rHMPV-Pa vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced May 22, 2026, 1:09 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Respiratory Syncytial Virus, Human Metapneumovirus
Interventions
mRNA-1345, mRNA-1365, Placebo, Nimenrix
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
5 Months to 24 Months
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
mRNA-1653, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Omaha, Nebraska • Austin, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Healthy
Interventions
IVX-A12, Placebo
Biological
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
10
States / cities
Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy
Interventions
IVX-121, IVX-241, Placebo, MF59®
Biological · Other
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Healthy Participants
Interventions
IVX-A12, Licensed RSV Vaccine
Biological
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years and older
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
5
States / cities
Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced May 22, 2026, 1:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
Interventions
RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
10
States / cities
Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
mRNA-1653, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced May 22, 2026, 1:09 AM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
PUL-042, Placebo
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Duarte, California • Atlanta, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 1:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
Interventions
RSV/hMPV mRNA LNP 1, RSV/hMPV mRNA LNP 2, RSV mRNA LNP 1, hMPV mRNA LNP 1
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
9
States / cities
Gardena, California • Hallandale, Florida • Meridian, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced May 22, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Viral Pneumonia
Interventions
SNG001, Placebo
Drug
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Sacramento, California • Torrance, California • Naples, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced May 22, 2026, 1:09 AM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions
artus Influenza A/B RT-PCR Test
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
Not listed
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced May 22, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Human Metapneumovirus, Human Parainfluenza Virus Type 3
Interventions
B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Months to 59 Months
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 22, 2026, 1:09 AM EDT